Insiders · CLYM

Robert Azelby

Officer, Director at Eliem Therapeutics, Inc. (CLYM)

Robert Azelby has filed 26 insider reports with the SEC since June 2021, as director at Cardinal Health Inc (CAH), director at Autolus Therapeutics plc (AUTL) and director at Tango Therapeutics, Inc. (TNGX) and at 5 more companies. Robert Azelby made no open-market purchases or sales in the last 12 months. The latest filing, on November 16, 2026, reports grant or award at Cardinal Health Inc (CAH).

Filings
26
Companies
8
Bought on market
None
Sold on market
$20.2K

Companies where Robert Azelby is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Cardinal Health Inc logo
CAH
Cardinal Health Inc
Directorsince March 20244,840$272.81Nov 16, 2026
Autolus Therapeutics plc logo
AUTL
Autolus Therapeutics plc
Directorsince March 2026$0.9073Jul 1, 2026
Tango Therapeutics, Inc. logo
TNGX
Tango Therapeutics, Inc.
Directorsince June 20265,740$21.73Jun 23, 2026
ADC Therapeutics SA logo
ADCT
ADC Therapeutics SA
Directorsince January 2024112,805$20.2K$1.28Jun 3, 2026
Terns Pharmaceuticals, Inc. logo
TERN
Terns Pharmaceuticals, Inc.
Directorsince February 2025May 5, 2026
Chinook Therapeutics, Inc. logo
KDNY
Chinook Therapeutics, Inc.
Directorsince April 2023Aug 11, 2023
Eliem Therapeutics, Inc. logo
CLYM
Eliem Therapeutics, Inc.
Officer, Director$9.19Nov 2, 2022
Clovis Oncology, Inc. logo
CLVS
Clovis Oncology, Inc.
DirectorJun 12, 2021

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Robert Azelby with

Other insiders at the same companies

Questions about Robert Azelby

What is Robert Azelby's role at Eliem Therapeutics, Inc.?
Robert Azelby reports to the SEC as officer and director at Eliem Therapeutics, Inc. (CLYM), according to the latest filing on November 2, 2022. Robert Azelby has also filed as director at Cardinal Health Inc (CAH), director at Autolus Therapeutics plc (AUTL), director at Tango Therapeutics, Inc. (TNGX) and director at ADC Therapeutics SA (ADCT).
How many shares does Robert Azelby own?
After the latest filing that states it, Robert Azelby directly owned 4,840 shares of Cardinal Health Inc (CAH), 5,740 shares of Tango Therapeutics, Inc. (TNGX) and 112,805 shares of ADC Therapeutics SA (ADCT). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Robert Azelby bought or sold stock recently?
The most recent open-market sale was on June 17, 2024: sold 6,995 shares of ADC Therapeutics SA (ADCT) for $20.2K at an average of $2.89.
How do I get alerts when Robert Azelby files?
Follow Robert Azelby on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Robert Azelby filed 1 time in the last 90 days.

From SEC Forms 3, 4, 5 and 144 filed by Robert Azelby (SEC CIK 0001656998). Totals count each trade once, skipping amendments whose original is on file, from Jun 12, 2021 on. View on SEC EDGAR · Get this as JSON